iRay Group

iRay Group FCF/Debt

The Free Cash Flow to Debt Ratio of iRay Group (688301.SS) as of Oct 15, 2026 is -10.35 %. In the previous year, Free Cash Flow to Debt Ratio was -30.52 % — a change of -66.10% (higher).

FCF/Debt

-10.35 %

YoY

-66.10%

Last updated:

Free Cash Flow to Debt Ratio of iRay Group is 2025 -10.35 % . Free Cash Flow to Debt Ratio of iRay Group was 2024 -30.52 % . It decreases by -66.10% higher compared to the previous year.

The iRay Group FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-286.15 CNY
Jan 1, 2019
-15.98 CNY
Jan 1, 2020
333.12 CNY
Jan 1, 2021
94.40 CNY
Jan 1, 2022
-27.96 CNY
Jan 1, 2023
-72.15 CNY
Jan 1, 2024
-30.52 CNY
Jan 1, 2025
-10.35 CNY
The iRay Group FCF/Debt history
YEARFCF/DebtYoY
-10.35 %-66.10%
-30.52 %-57.70%
-72.15 %+158.01%
-27.96 %-129.62%
94.40 %-71.66%
333.12 %-2,184.16%
-15.98 %-94.41%
-286.15 %-120.44%
1,399.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iRay Group Stock analysis

What does iRay Group do? iRay Group, operating under the ticker symbol 688301.SS and identified by ISIN CNE1000042V8, is a prominent entity within the Chinese healthcare sector. Headquartered in Shanghai, the company has established itself as a significant player in the medical technology industry, specifically focusing on the development and manufacturing of advanced digital imaging solutions. The organization went public on September 18, 2020, marking a pivotal moment in its corporate history and allowing it to expand its operational capabilities on a broader scale. As of the latest available data, iRay Group employs a workforce of 1,237 full-time employees, reflecting its substantial operational footprint and commitment to human capital in driving technological innovation. The core business of the company revolves around the research, development, production, and sale of digital X-ray detectors, which are critical components in modern medical diagnostic equipment. These detectors are engineered to provide high-resolution imaging, enabling healthcare professionals to make accurate and timely diagnoses. The product portfolio of iRay Group is diverse and tailored to meet various clinical and industrial needs. Key product lines include the universal radio frequency series, which offers versatile imaging solutions for general diagnostic purposes. Additionally, the company manufactures specialized breast series detectors designed specifically for mammography, ensuring high sensitivity and image clarity for early detection of breast abnormalities. The radiotherapy series further expands the company's reach into therapeutic applications, providing essential imaging support for radiation treatment planning and monitoring. Beyond the medical sector, the technology developed by iRay Group finds application in industrial non-destructive testing and security inspection fields. This diversification highlights the robustness of their detector technology, which can be adapted for inspecting materials integrity in manufacturing or screening for security threats. The company maintains a comprehensive distribution network that serves both the domestic market within China and international markets overseas. This global reach underscores the competitive quality of their products and the company's strategic focus on expanding its presence in the worldwide healthcare and industrial technology sectors. By leveraging its expertise in digital X-ray technology, iRay Group continues to contribute to advancements in medical diagnostics and industrial safety, positioning itself as a key innovator in the health care industry. iRay Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iRay Group stock

Free Cash Flow to Debt Ratio of iRay Group is -10.35 % in 2025.

Free Cash Flow to Debt Ratio of iRay Group changed from -30.52 % to -10.35 %, representing a -66.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio iRay Group since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's iRay Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — iRay Group

All Key Metrics — iRay Group